Prime Medicine Inc (PRME) Actualités

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 30, 2025...

Form 8-K - Current report

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology...

Form EFFECT - Notice of Effectiveness

Form S-3 - Registration statement under Securities Act of 1933

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

-- Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT;...

Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology...

Form 8-K - Current report

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety...

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

-- On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA...

Form 8-K - Current report

Prime Medicine Unveils Strategically Focused Pipeline

-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform...